Atara Biotherapeutics Inc (NASDAQ:ATRA) – Equities research analysts at William Blair boosted their Q1 2018 earnings estimates for shares of Atara Biotherapeutics in a report issued on Tuesday. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($0.89) per share for the quarter, up from their previous estimate of ($1.08). William Blair also issued estimates for Atara Biotherapeutics’ Q2 2018 earnings at ($0.88) EPS, Q3 2018 earnings at ($0.90) EPS, Q4 2018 earnings at ($0.92) EPS, FY2018 earnings at ($3.59) EPS, FY2019 earnings at ($4.00) EPS, FY2020 earnings at ($3.06) EPS and FY2021 earnings at ($2.20) EPS.
Several other research analysts have also recently issued reports on ATRA. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a report on Thursday, November 9th. ValuEngine upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Citigroup upgraded shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a report on Wednesday, January 3rd. BidaskClub upgraded shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Finally, Cowen initiated coverage on shares of Atara Biotherapeutics in a research note on Friday, January 26th. They set an “outperform” rating for the company. Two analysts have rated the stock with a sell rating, two have issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $30.60.
In related news, EVP Heather D. Turner sold 12,214 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $38.01, for a total transaction of $464,254.14. Following the completion of the sale, the executive vice president now owns 77,112 shares in the company, valued at approximately $2,931,027.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Gad Soffer sold 7,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $15.00, for a total transaction of $105,000.00. Following the sale, the executive vice president now owns 166,342 shares of the company’s stock, valued at approximately $2,495,130. The disclosure for this sale can be found here. In the last quarter, insiders have sold 297,914 shares of company stock valued at $8,074,587. 16.20% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the business. Pacific Heights Asset Management LLC purchased a new position in Atara Biotherapeutics during the 4th quarter worth $453,000. Schwab Charles Investment Management Inc. raised its position in Atara Biotherapeutics by 16.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 92,974 shares of the biotechnology company’s stock worth $1,302,000 after buying an additional 13,394 shares during the last quarter. Perceptive Advisors LLC purchased a new position in Atara Biotherapeutics during the 3rd quarter worth $581,000. Essex Investment Management Co. LLC purchased a new position in Atara Biotherapeutics during the 3rd quarter worth $429,000. Finally, Vanguard Group Inc. raised its position in Atara Biotherapeutics by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock worth $11,842,000 after buying an additional 13,952 shares during the last quarter. Institutional investors own 69.58% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.